Development of antibody-drug conjugate to diagnose and treat vulnerable plaque

2017 Fiscal Year Final Research Report

• Project/Area Number: 15H04821
• Research Category: Grant-in-Aid for Scientific Research (B)
• Allocation Type: Single-year Grants
• Section: 一般
• Research Field: Cardiovascular medicine
• Research Institution: Kagawa University (2016-2017); Osaka University (2015)
• Principal Investigator: MINAMINO TETSUO 香川大学, 医学部, 教授 (30379234)
• Co-Investigator(Kenkyū-buntansha): 浅井 知浩 静岡県立大学, 薬学部, 准教授 (00381731) ; 松崎 高志 香川大学, 医学部, 研究員 (90456939) ; 村上 和司 香川大学, 医学部附属病院, 講師 (60575207) ; 野間 貴久 香川大学, 医学部附属病院, 准教授 (20363202) ; 富 海英 大阪大学, 医学系研究科, 特任助教(常勤) (70754646) ; 羽尾 裕之 日本大学, 医学部, 教授 (40393243)
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: HB-EGF抗体

Outline of Final Research Achievements

We have developed the new antibody against HB-EGF (anti-HB-EGF Ab) that can be internalized into the cell after binding. In atherosclerotic lesions, especially vulnerable plaque, the expression of HB-EGF markedly increased. When we administered anti-HB-EGF labeled with siRNA into severe atherosclerosis mouse model, we find that anti-HB-EGF labeled with siRNA efficiently reduced the expression of target molecules with reduced severity of atherosclerosis. Anti-HB-EGF Ab is a promising tool for the diagnosis and therapy for vulnerable plaque.

Free Research Field

循環器内科